RESEARCH CONSOLE // COLOPHON
About Meds TB-500: an independent reading of the TB-500 research record.
Who runs this console, what "meds" means here, and the line we keep clear between editorial commentary and clinical or commercial activity.
What this site is
Meds TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 — the Ac-LKKTETQ fragment of thymosin beta-4 — and on its parent protein. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a research console for a reason. TB-500's record is thin, mixed, and partly cautionary: a confirmed actin-sequestration structure [1], a strong set of animal repair findings [3], real null results [9][14], a genuine tumor-and-angiogenesis safety signal [7][8], and zero completed controlled human trials of the fragment [5]. Telling that honestly means separating what the literature confirms from where the data warn or stop — and tagging every datum with the molecule it actually came from, because most efficacy data are for full-length thymosin beta-4, not the 7-mer [5].
What "meds" means in the name
The "meds" in this domain is editorial framing — a position this publisher occupies relative to the literature, the regulatory record, and the question of how lawful compounded access works [17]. It is not a claim about services. This site has no pharmacy, fills no prescriptions, stocks no inventory, and offers no consultation. It does not implicate any doctors, pharmacists, or clinical team, because it has none. When the site discusses TB-500 legal status and FDA 503A category, it is summarizing FDA's published record [16], not offering to help anyone obtain anything.
We keep that distinction explicit because the subject invites confusion. A research peptide with a flagged regulatory status and an active FDA review attracts both genuine curiosity and commercial noise. This site is on the curiosity side of that line, and only there.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in the references register, drawn from PubMed-indexed journals and, for the regulatory page, FDA primary sources [16][17][18]. We do not present community "loading" protocols as validated dosing, because they are not [5]. We do not state any FDA reclassification as completed or dated, because FDA's last confirmable action places TB-500 in Category 2 [16]. And we preserve the identity caveat — fragment versus full-length thymosin beta-4 — on every finding, because it is the difference between reading the literature accurately and reading it the way a product page would [5].